Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence Source: Eur Respir J, 53 (1) 1801038; 10.1183/13993003.01038-2018 Year: 2019
Long-term survival of patients with mycobacterium avium- intracellulare complex pulmonary disease (MAC-PD) Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection Source: Eur Respir J 2015; 46: 1823-1826 Year: 2015
Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016